Agents Used in Antiretroviral Therapy
Summary
- Cobicistat is a CYP3A inhibitor used as a pharmacologic booster for atazanavir, darunavir, and elvitegravir at a daily dose of 150 mg (Table 13)[FDA Cobicistat]
- Baseline CrCl should be assessed before initiating treatment
- When cobicistat is administered with tenofovir DF or tenofovir AF, baseline urine glucose and urine protein should also be assessed[FDA Cobicistat; FDA COBI/EVG/FTC/TAF]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content